BridgeBio Oncology Therapeutics, Inc. (BBOT)

BridgeBio Oncology Therapeutics, Inc. (BBOT) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $265M; returns 1 day -6.7%, 1 week -5.7%, 1 year -75.5%.

BridgeBio Oncology Therapeutics, Inc. (NASDAQ: BBOT) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics for cancers driven by RAS and PI3Kα pathway malignancies. The company's business model is centered on advancing its precision oncology pipeline through clinical trials with the goal of eventual commercialization.

Groups BBOT belongs to

• Clinical Stage Biotech
• Oncology
• Biotechnology
• Biopharmaceutical
• Precision Medicine
• Healthcare
• Cancer Therapeutics
• Life Sciences
• Clinical Stage

BBOT financial model: income statement, cash flow and balance sheet